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The development of in vitro assays for the growth of clonogenic tumour cells in soft agar (Hamburger & Salmon, 1977; Hamburger et al., 1978) suggested a system which might be of benefit, not only in selecting chemotherapeutic regimes following surgical ablation of tumour, but also in identifying those drugs to which a patient might be sensitive after extensive pretreatment. Success in using such a system has been claimed by Alberts et al. (1980a) who predicted clinical response based on in vitro tests in 62% of patients with ovarian cancer and had an accuracy of 99% in the prediction of resistance.
Following a pilot study with a small number of ovarian tumours (Simmonds et al., 1981) this investigation was undertaken with the aims of (i) culturing ovarian tumour material using the stem cell or clonogenic assay, (ii) evaluation of drug sensitivity to agents in current clinical use and (iii) correlation of these results with clinical outcome.
It was decided that the methods outlined by Hamburger & Salmon (1977) Assessment of response to cis-platinum and adriamycin was made using the "sensitivity indices" for area under the curve described by Alberts et al. (1980a, b) and based on a <50% survival at 10% the peak plasma concentration on a log linear dose response curve for phosphoramide mustard. Only samples with a minimum of 30 colonies in control plates were evaluated for drug sensitivity.
Clinical data Information about clinical response was obtained through the West of Scotland Clinical Trials Unit at Glasgow University Department of Clinical Oncology, courtesy of Prof K.C. Calman. Forms designed for the purpose were sent out at 6-month intervals to the consultants involved, requesting details of disease status, response to the chemotherapeutic regime of choice and plans for future management. Responses were measured by palpation, CAT scan and "second-look" laparotomy. A complete response (CR) was denoted by complete disappearance of all clinically detectable malignancy for at least 4 weeks and a partial response (PR) was classified as an objective decrease in measurable tumour mass by 50%. All such information received was correlated with the drug results obtained.
Results

Culture
Successful culture as measured by colony formation of at least 10 colonies per dish at 10 days was observed for all the histological tumour types received and in every type of sample. Plating efficiencies observed were in the range 0.009% to 0.6% in control plates, although the majority of samples (60%) had PEs of between 0.01% and 0.1%. This still excluded many samples from assessment for significant drug results. To assess the precision of the scoring technique, the values for 48 samples were analysed and the coefficient of variation calculated for each set of replicate determinations, including drug treated plates. In the range of colonies counted 6-1025, the mean coefficient of variation was 12.4%.
To exclude the possible influence of extreme values, the mean coefficient of variation was recalculated in the range 10-100 colonies and found to be 11.4%. This represented 39 of the 48 samples.
Linearity of colony formation
For 6 samples studied, a linear relationship was observed between the number of nucleated cells plated and the number of colonies formed. This held good over the range studied, from 5 For phosphoramide mustard, percentage survival at 10% the peak plasma concentration (3.5 ug ml-1) was calculated and samples classified as sensitive if fewer than 50% of the colonies survived at this concentration.
Response to cis-platinum Patterns of response of ovarian tumour samples to cis-platinum are shown in Figure 1 . The response of material from untreated patients is shown in Figure la and b and that from pre-treated patients in Figure Ic and Of the 5 samples exposed to cis-platinum previously (Figure lc and d) one retained sensitivity while the others were markedly resistant.
Response to adriamycin The results with adriamycin ( Figure 2 ) were similar to those observed for cis-platinum. Of the 30 samples not previously exposed to this drug (Figure 2a and b) , 26 (87%) representing 76% of patients were markedly sensitive and 4 were resistant.
Of the 5 samples previously exposed to adriamycin (Figure 2c and d) only one was sensitive while the remainder were resistant.
Response to phosphoramide mustard The response of the 9 samples tested is shown in Figure 3 . None had previously been exposed to cyclophosphamide. Two samples were sensitive and the remainder were resistant.
Relationship between drug sensitivities Untreated material In samples from patients who had not received any cytotoxic therapy, those sensitive to adriamycin were also sensitive to cisplatinum with 5 exceptions. In 4 of these instances, the samples were judged to have an intermediate (') = pretreated; R = resistant; S = sensitive; + = response; P = progression; 0 = stable; Y = yes; N = no; ? = equivocal. culture rate of 69% compares favourably with those reported by other workers (Hamburger et al., 1978; Ozols et al., 1980a) .
We have also demonstrated that 60% of samples representing 48% of previously untreated patients were sensitive to cis-platinum and that this number may be higher if "intermediate" values are regarded as sensitive. Only 17% of untreated samples were overtly resistant to cis-platinum. Similarly, 87% of untreated samples were markedly sensitive to adriamycin when tested and only 13% were resistant. These values for adriamycin compare with those of Ozols et al. (1980b) who used the same period of drug incubation but different parameters for sensitivity (70% reduction in colony forming cells at clinically achievable plasma levels).
Sensitivity to phosphoramide mustard in culture was observed in only 22% of samples, but it may be that the parameters for sensitivity discrimination were too stringent. Additionally, it has been suggested (Powers & Sladek, 1983 ) that phosphoramide mustard might not be the active metabolite in patients where cyclophosphamide is of therapeutic value. As the group of patients was small and few received this chemotherapy, it has not been possible to make adjustments based on clinical outcome.
Although the group of patients pretreated with cis-platinum and adriamycin was small, it has been demonstrated that 80% of samples taken from such patients are overtly resistant to these drugs. These figures for adriamycin again concur with those of Ozols et al. (1980b) Any discussion of the relative merits of the clonogenic assay must include (a) analysis of its performance as a useful, reproducible laboratory procedure and (b) its possible clinical usefulness in the management of cancer patients and how this may be achieved.
The performance of this assay as a reproducible test in the laboratory has been established and the percentage of samples cultured successfully compares well with workers using other methodologies (Wilson & Neal, 1981) .
Our culture success rates are superior to those of Williams et al. (1983) but in common with these and other workers, we have reservations about the low plating efficiencies associated with this method (Bertoncello et al., 1982; Rupniak & Hill, 1980) . As a consequence of this, too few samples are evaluable for drug study. Although 62% of our samples gave drug results in comparison to Von Hoff et al. (1981) who found that only 25% of samples were evaluable, in practice this number was much lower once changes in therapeutic regimes had been accounted for. Studies by Courtenay & Mills (1978) have indicated that it is possible to improve plating efficiencies and colony size by a combination of low oxygen and the presence of rat RBC, although there is not general agreement that the RBC are necessary (Pavelic et al., 1980) . It is clear that some modifications along these lines are necessary to improve performance of this test.
Similarly, small sample size is a problem which has greater implications for the production of drug results than is true for assays which depend on the establishment of monolayers, since the number of cells derived at the outset determines the number of tests which may be made (Bertoncello et al., 1982) . Samples from "first" laparotomies are often generous, but it is at "second-look" laparotomies or the tapping of effusions from patients who have progressed, that the provision of samples large enough for drug testing for possible second-line chemotherapy is vital. It is at this time either that samples cannot be obtained or the cell yield is too low. From a consideration of technical limitations, therefore, it is clear that, not only must culture conditions be modified to improve plating efficiency but that several drugs which the patient has not received be tested at one concentration alone to maximise the use of material.
The potential of the clonogenic assay in the clinical context could be realised by the adoption of several strict procedures. All the likely chemotherapy for a particular patient should be tested at the outset. Although most centres enter all suitable patients into clinical trials and few use single agent chemotherapy, the testing of 4 or 5 drugs should cover all possible treatment. Therefore, each sample should be split so that these drugs can be tested at single concentrations representing 10% of the peak plasma concentration. Sensitivity would be determined as a less than 50% survival at these concentrations. The majority of samples would be sensitive under these conditions, but a significant number may exhibit resistance to one or more drugs. If the resistance is to cis-platinum, it is unlikely that patients would respond to other alkylating agents.
Samples from patients who have progressed on their chemotherapy should only be tested against drugs which they have not received, if sample sizes are small. Such tests should be able to demonstrate any residual sensitivity.
In this way, the fullest possible information about likely response to chemotherapy would be made available for use in management. Although it is unlikely that fixed regimes would be changed as a result of these tests, this assay may have considerable benefit in the choice of drugs for patients who have relapsed.
It is clear that the usefulness of this assay in determining patient management remains to be tested. The value of such an in vitro system lies in predicting resistance in those groups of previously untreated patients who will fail to respond to their chemotherapy and in predicting sensitivity in patients who have progressed on their existing regimes or who for other reasons, such as toxicity or second-line chemotherapy for residual disease, require alternative drugs. No useful clinical information can be gained by testing drugs to which a patient is already demonstrably clinically resistant and such demonstrations do nothing to validate this system.
